查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571764

肺癌诊断市场规模、份额、趋势分析报告：按类型、测试、最终用途、地区、细分市场预测，2024-2030 年

Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肺癌诊断市场的成长与趋势：

Grand View Research Inc.最新报告显示，预计2030年全球肺癌诊断市场规模将达72.6亿美元，2024年至2030年复合年增长率为6.5%。

肺癌特异性生物标记的开拓是预测期内肺癌诊断市场成长的关键驱动力之一。这些诊断工具促进了肺部恶性的个人化治疗方法。

研究管道中存在多种生物标记。例如，2015 年 11 月，Epigenomics AG 宣布推出一种使用 DNA 甲基化生物标记的新型血液测试，该测试的开发正在进行中。该测试的初步结果显示了肺癌早期诊断的有希望的结果。

此外，还启动了各种针对肺癌及相关症状的宣传计划，以提高恶性高风险族群的筛检和诊断率。例如，11 月是英国的肺癌宣传月，由罗伊城堡肺癌基金会支持。

肺癌诊断市场报告亮点

  • 2023年，非小细胞肺癌（NSCLC）领域将占据主导地位，并占据可观的收益占有率。 NSCLC又分为肺鳞状细胞癌、腺癌和大细胞癌。
  • EGFR突变检测在2023年占据市场主导地位，市场占有率为29.2%。表皮生长因子受体（EGFR）是 NSCLC 患者中最常见的激动性突变之一。
  • 医院和诊所细分市场在 2023 年占据主导地位。这是因为我们的设施拥有先进的诊断工具和影像技术，可以准确检测和分期肺癌。
  • 由于先进的医疗基础设施、高昂的医疗成本以及严格的癌症诊断报销规定，北美在 2023 年将主导全球肺癌诊断市场。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章肺癌诊断市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肺癌诊断市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肺癌诊断市场：按类型估计和趋势分析

  • 细分仪表板
  • 肺癌诊断市场：2023 年和 2030 年按类型分類的变异分析
  • 非小细胞肺癌
  • 小细胞肺癌

第五章肺癌诊断市场：透过测试进行的估计和趋势分析

  • 细分仪表板
  • 肺癌诊断市场：2023 年和 2030 年测试变异分析
  • CA测试
  • HER2测试
  • ALK测试
  • 血管新生抑制剂
  • EGFR突变检测
  • KRAS突变测试

第六章肺癌诊断市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 肺癌诊断市场：2023 年和 2030 年最终用途的变异分析
  • 医院和诊所
  • 诊断实验室
  • 其他的

第七章肺癌诊断市场：按地区估算及趋势分析

  • 2023 年及 2030 年肺癌诊断市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific
    • Illumina Inc.
    • Agilent Technologies
    • Qiagen
    • Abbott
    • Bio-Rad
    • Neogenomics Laboratories
    • bioMerieux
    • Myriad Genetics, Inc
简介目录
Product Code: 978-1-68038-888-6

Lung Cancer Diagnostics Market Growth & Trends:

The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.

Lung Cancer Diagnostics Market Report Highlights:

  • The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
  • EGFR mutation tests dominated the market with a 29.2% market share for 2023. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.
  • The hospitals and clinics segment dominated the market in 2023. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.
  • North America dominated the global lung cancer diagnostics market in 2023 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Lung Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Lung Cancer Diagnostics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Lung Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, USD Billion, 2023 & 2030
  • 4.3. Non-small Cell Lung Cancer
    • 4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Small Cell Lung Cancer
    • 4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lung Cancer Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, USD Million, 2023 & 2030
  • 5.3. CA Tests
    • 5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. HER2 Tests
    • 5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. ALK Tests
    • 5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Angiogenesis Inhibitors
    • 5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. EGFR Mutation Tests
    • 5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. KRAS Mutation Tests
    • 5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lung Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Hospitals and clinics
    • 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Diagnostic Laboratories
    • 6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lung Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Lung Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Thermo Fisher Scientific
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Illumina Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Agilent Technologies
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Qiagen
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Abbott
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Bio-Rad
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Neogenomics Laboratories
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. bioMerieux
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Myriad Genetics, Inc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives